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Abstract 
Knee osteoarthritis (OA) is a heterogeneous disease, and identification of its 
subgroups/phenotypes can improve patient treatment and drug development. We aimed to 
identify homogeneous OA subgroups/phenotypes using pain development over time; to 
understand the interplay between pain and functional limitation in time course, and to 
investigate subgroups’ responses to available pharmacological and surgical treatments. We 
used group-based trajectory modelling to identify pain trajectories in the phase-three VIDEO 
trial (n=474, three-year follow-up) and also in the Osteoarthritis Initiative cohort study 
(n=4796, nine-year follow-up). We extended trajectory models by (1) fitting dual trajectories 
to investigate the interplay between pain and functional limitation over time, and (2) 
including analgesic use as a time-varying covariate. Also, we investigated the relationship 
between trajectory-groups and knee replacement in regression models. We identified four 
pain trajectory-groups in the trial and six in the cohort. These overlapped and led us to define 
four OA phenotypes: low-fluctuating, mild-increasing, moderate-treatment-sensitive and 
severe-treatment-insensitive pain. Over time, functional knee limitation followed the same 
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trajectory as pain with almost complete concordance (94.3%) between pain and functional 
limitation trajectory-groups. Notably, we identified a phenotype with severe pain that did not 
benefit from available treatments, and another one most likely to benefit from knee 
replacement. Thus, knee OA subgroups/phenotypes can be identified based on patients’ pain 
experiences in studies with long and regular follow-up. We provided a robust approach, 
reproducible between different study designs that informs clinicians about symptom 
development and delivery of treatment options and opens a new avenue toward personalized 
medicine in OA. 
Keywords: pain; osteoarthritis; group-based trajectory modelling; phenotype 
 
 
1. Introduction  
Pain is the primary symptom and descriptor of the burden of osteoarthritis (OA), a chronic 
disease related to substantial disability, morbidity and costs [29]. According to 2010 
estimates, it is globally among the top contributors to disability [7; 22]. The socioeconomic 
burden of OA includes direct expenditure on non-pharmacological and pharmacological 
treatments, with indirect costs from productivity loss, early retirement and premature death 
[13]. For individuals, long-term outcomes include pain, functional limitations of the affected 
joint and reduced quality of life. Currently availa
ble treatment options – both 
pharmacological for pain/symptom management and surgical, i.e. joint replacement – do not 
provide significant improvements to all patients [30; 31]. 
8 8
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The need for successful development of treatment options for all OA patients is currently 
unmet. While treatment is expected to halt or minimise OA progression, pain relief is the 
essential determinant of cost-effectiveness [8]. There have been considerable efforts to 
develop OA treatment, with many promising candidates failing to reach endpoints in phase-
three clinical studies. This challenge has been explained by heterogeneity, indicating that OA 
requires personalised medicine [12; 17; 28]. Thus, to improve drug development and reduce 
OA burden, the proper identification of phenotypes – distinct groups of patients that share the 
same pathophysiology – is required [21]. These phenotypes will help in selecting patients 
most likely to benefit from specific treatment options. 
In this study, we hypothesised that OA phenotypes could be identified by patients’ 
pain/symptom experiences over time. We focused on the most common one: knee OA [12]. 
We used a phase-three clinical trial as a typically selected clinical OA population, and a more 
extensive prospective cohort study for the external validation. We intended to identify pain 
patterns/trajectories and to explore the interplay between pain and functional limitation 
development over time, as both are outcomes of interest. To identify if and how phenotypes 
respond to available pharmacological treatments, we investigated the effect of medication 
over time. We also studied whether pain trajectory-groups are associated with surgical 
outcomes. Finally, we explored the baseline characteristics associated with each phenotype, 
as these could provide evidence-based recommendations for core phenotyping in 
personalised medicine and trial recruitment. 
 
2. Methods 
2.1. Study samples 
The Vitamin D Effect on Osteoarthritis (VIDEO) trial was designed to investigate the effect 
of vitamin D supplementation (daily 800 IU oral cholecalciferol) on knee OA progression. It 
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was a multi-centre, three-year, double-blind, placebo-controlled randomised clinical trial 
approved, registered and performed in the United Kingdom (EudraCT: ref.2004-000169-37, 
ISRCTN94818153, CTA No.11287/0001/001) [2]. Participants were included if older than 50 
years with radiological evidence of knee OA and knee pain for most days of the month. 
Exclusion criteria were: morning knee stiffness longer than thirty minutes, secondary or 
inflammatory arthritis, history of knee surgery or knee replacement in previous six months, 
osteoporotic fractures, use of bisphosphonates, supplements containing vitamin D, and 
glucosamine and chondroitin less than three months. For further details, see Arden et al. [2]. 
Although an interventional study, for this work, the VIDEO trial was utilised as an 
observational typically selected clinical OA study sample. 
The Osteoarthritis Initiative (OAI) study is a prospective observational study of knee OA 
sponsored by the National Institute of Health. Participants age 45-79 were recruited at four 
centres across the United States. Exclusion criteria were: inflammatory arthritis, severe joint 
space narrowing, bilateral knee replacement or plans for it in the next three years, 
comorbidities that might interfere with participation in this study, participation in clinical 
trials and others. Additional study details, as well as data, are available at the 
https://nda.nih.gov/oai. As of February 2019, data were available through the ninth-year visit.  
Participants in both studies provided written informed consents.  
2.2. Outcome measures 
The primary outcome in this study was the pain subscale of the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) [5] – a total score of five questions 
scaled from zero (no pain) to 100 (extreme pain). In the VIDEO trial, pain was assessed for 
the index knee as previous 48 hour-recall at six-month intervals (seven repeated measures). 
In the OAI study, the timeframe of pain assessment was previous seven days at annual 
intervals (ten repeated measures). There were reports for the left and right knee irrespective 
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of the disease. We assigned a more painful knee throughout the visits for result 
generalisation. 
The secondary outcomes in this study were the functional limitation subscale of the WOMAC 
[5], assessed and scaled like the pain subscale (0-100), and surgical outcome, i.e. knee 
replacement. In the VIDEO trial, knee replacement was recorded at the end of the trial as 
binary outcome. In the OAI study, exact dates of the knee replacements were recorded 
throughout the follow-up.  
2.3. Covariates 
Baseline variables were used for descriptive purpose and to assess their impact on the pain, as 
well as confounding variables when the pain was related to the surgical outcome. Age, sex, 
smoking, alcohol use, employment status, and use of supplements, glucosamine and 
chondroitin, were self-reported. Body mass index (BMI) was computed based on height and 
weight measurements. In the VIDEO trial, depression was assessed by Beck’s Depression 
Inventory containing 21 questions summed to the total score (0-63). [4] In the OAI study, 
Centre for Epidemiological Studies Depression Scale with 20 items and a total score 0-60 
was used. [20] In both questionnaires, a higher score indicates worse symptomatology. In the 
VIDEO trial only, physical activity (once or more times per month) and quality of life were 
assessed. The short version of the World Health Organization Quality of Life (WHOQoL-
Bref) contains 26 questions measuring four domains, physical health, psychological health, 
social relationships, and environment each scoring from zero to 100. Higher scores denote a 
better quality of life. [10] Comorbidities, defined as none, one or more than one, were 
recorded in the OAI study only. A trained orthopaedic fellow or radiologist scored the 
radiographs according to the Kellgren-Lawrence (KL) grades [18].  
Use of currently available medications that affect pain levels, directly or indirectly, i.e. 
analgesics, non-steroid anti-inflammatory drugs and steroids, further referred as analgesics, 
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was recorded in both studies throughout follow-up and used in the primary analysis as a 
binary time-varying covariate. Mortality during follow-up was used for descriptive purposes 
and sensitivity analyses. Missing values were shown per variable; these were not imputed and 
were considered for analyses if the percentage was less than 10%. 
2.4. Statistical analysis 
Firstly, we showed baseline characteristics of our study samples for descriptive purposes. 
Further, we conducted our analyses in three steps: identification of trajectories with two 
extensions, investigating the association of pain trajectories with distal surgical outcome, and 
identification of baseline factors for predicting trajectories.  
To identify trajectory-groups (latent clusters of individuals) that follow a similar pattern of 
how pain develops over time, we used group-based trajectory modelling [23]. We used 
censored normal models with up to a fourth-order polynomial and tested a different number 
of trajectory-groups. Statistical criteria, Bayesian information criteria (BIC) [15] and group 
posterior probability (>0.70) [24], aided in selecting the best model fit [1; 16]. We also used 
the Wald test for equality of trajectory coefficient estimates to confirm that trajectories are 
distinctive or parallel [14]. Our trajectories were related to the index knee in the VIDEO trial, 
and more painful knee in the OAI study. After fitting pain trajectories, we included two 
model extensions, dual trajectories and time-varying covariate [14]. Dual trajectory 
modelling is analysing the developmental course of two different but related outcomes [25]. 
Here, we looked into pain and functional limitations. We modelled functional limitation 
trajectories in the same manner as pain trajectories. Then in the dual trajectory model, we 
examined pain development over time, given the information from function limitation 
trajectories. This analysis provides conditional probabilities joining membership across the 
pain and functional limitation trajectory-groups [14]. In the last section of trajectory 
modelling, we included analgesic use as time-varying covariates into pain trajectory model 
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[14]. It is a binary variable, as the purpose of this sub-analysis was to find whether currently 
available analgesics significantly reduced pain over time providing the effect estimates per 
trajectory-groups (the strata of indication severity).  
To investigate the association between pain trajectory-groups and knee replacement, in the 
VIDEO trial, we used a logistic regression forward selection method. In the OAI study, we 
conducted a time-to-event analysis using the Cox proportional-hazards forward selection 
model. 
To identify baseline factors associated with pain trajectory membership and to differentiate 
each trajectory-group, we used a multinomial regression forward selection method. We 
created several models with different trajectory-groups of interest as referenced ones. 
As sensitivity analyses, we remodelled pain trajectories excluding mortality cases during the 
follow-up. Further, in the OAI study, we investigated the left and right knee pain trajectories. 
Also, dual left and right trajectories, i.e. modelling left knee pain development over time 
having the right knee pain trajectories.  
We analysed the data using SAS 9.4 (SAS Institute, Cary, North Caroline). We used proc traj 
package with macros trajtest and trajplotnew available at 
https://www.andrew.cmu.edu/user/bjones/. 
 
3. Results 
The VIDEO trial included 474 participants, while the OAI study had 4796. Table 1 contains 
baseline characteristics of the study samples. Descriptive statistics, including missing values 
of pain, functional limitation and analgesic use variables at every follow-up visit used for the 
trajectory modelling, are included in Appendix (available as supplemental digital content at 
http://links.lww.com/PAIN/B88). 
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3.1. Trajectories 
We identified four pain trajectories described by the first-order curves in the VIDEO trial 
(Figure 1a, Table 2). The classification of individuals in pain trajectory-groups measured by 
the posterior probability of membership was very good: ranging from 0.85 to 0.91. The Wald 
test confirmed that the intercepts of all trajectories were statistically, significantly different 
from each other. The fourth trajectory was parallel (the slope was not statistically different) to 
the second (χ2=3.11, p=0.08) and third trajectory (χ2=0.01, p=0.93), while all others differed. 
The second trajectory model included dual trajectories. The best model fit identified four 
first-order curves that described functional limitation development (Figure 1b, modelling 
details in Appendix, available as supplemental digital content at 
http://links.lww.com/PAIN/B88). Functional limitation trajectories minimally affected the 
classification of pain trajectory-groups in the dual model (Table 2). Joint probabilities of pain 
and functional limitation trajectory-groups showed that 92.0% of individuals classified in the 
overlapping groups (Appendix, available as supplemental digital content at 
http://links.lww.com/PAIN/B88). Finally, in the third trajectory model, analgesic use had a 
significant positive effect on reducing pain in the first and second trajectory-groups and 
minimally affected the classification of pain groups compared to the primary model (Table 
2).   
In the OAI study, we identified six trajectories described by higher-order curves; the first and 
fourth trajectories described by cubic curves, the second one with quartic, and third, fifth, and 
sixth with quadratic curves (Figure 1c, Table 2). Posterior probabilities were very good, 
ranging from 0.80 to 0.90. Intercepts of pain trajectories were different; only group four and 
five intercepts were not different (χ2=0.50, p=0.47). Other parameters were compared 
between curves of the same order. The cubic curves were not parallel: all parameters were 
statistically significantly different. The quadratic curves of the fifth and sixth trajectory were 
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parallel (linear component χ2=2.70, p=0.10; quadratic component χ2=2.52, p=0.11), while the 
third trajectory was significantly different from these two. For the second – dual trajectory 
model – we identified six functional limitation trajectories (Figure 1d, modelling details in 
Appendix, available as supplemental digital content at http://links.lww.com/PAIN/B88). 
Additional information on functional limitation development over time introduced slight 
changes into the pain trajectory-groups (Table 2). Joint probabilities of pain and functional 
limitation development showed that 94.3% of individuals were classified in overlapping 
groups (Appendix, available as supplemental digital content at 
http://links.lww.com/PAIN/B88). Finally, for the third trajectory model in this study, we had 
to remodel pain trajectories without time point three, as use of analgesics was missing 
completely (Appendix, available as supplemental digital content at 
http://links.lww.com/PAIN/B88). The remodelled pain trajectories fully reflected those from 
the original model, with neglected alterations (Appendix, available as supplemental digital 
content at http://links.lww.com/PAIN/B88). Analgesics’ use had a significant positive effect 
in all trajectory-groups except the sixth and affected the classification of fourth and fifth pain 
groups. 
3.2. Risk for the distal outcome 
We found that no single pain trajectory-group in the VIDEO trial was significantly associated 
with index knee replacement during the three-year follow-up. In the OAI study, third, fourth 
and fifth groups but not the sixth had significantly higher hazard ratio of having knee 
replacement during the nine-year follow-up when compared to the second group (Table 3), 
and all groups when referenced to the first group (Appendix, available as supplemental 
digital content at http://links.lww.com/PAIN/B88). The highest hazard ratio was in the fourth 
group.  
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3.3. Descriptors of the pain trajectories 
Table 4 contains baseline characteristics of the trajectory-groups from both studies. 
In the VIDEO trial, we created two models using the first and fourth trajectory-group as 
references. The higher BMI and the lower physical domain of WHOQoL-Bref were 
associated with being in all groups compared to the first group. The higher psychological 
domain of WHOQoL-Bref was associated with membership of the second and third 
trajectory-groups. The second model aimed to distinguish the third and fourth groups: 
however, no single analysed variable showed a significant result (Appendix, available as 
supplemental digital content at http://links.lww.com/PAIN/B88). 
In the OAI study, the first, fourth and sixth groups were of interest, and we created three 
models using each as a reference. Members of any painful group, compared to those with 
minimal pain, were significantly more likely to be younger women with higher BMI, 
depression score, KL grade two or more and using painkillers. The membership in the fifth 
group compared to the fourth group was only negatively significantly associated with KL 
grade one. Finally, older age, lower BMI, lower depression score, and use of supplements 
were significantly associated with the fourth and fifth group compared to the sixth group. 
Other variables showed limited potential in distinguishing the pain groups (Appendix, 
available as supplemental digital content at http://links.lww.com/PAIN/B88). 
3.4. Sensitivity analyses 
Remodelled pain trajectories without mortality cases were the same as in the original model 
(Appendix, available as supplemental digital content at http://links.lww.com/PAIN/B88). In 
the OAI study, we identified six left and six right knee pain trajectories, described by higher-
order curves like the original/generalised pain trajectory model. In the dual trajectory model, 
left knee pain development slightly changed in terms of group percentage and posterior 
probabilities, given the additional information on right knee pain trajectories. Joint 
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probabilities showed that 64.2 of individuals were classified in the overlapping left and right 
knee pain groups (Appendix, available as supplemental digital content at 
http://links.lww.com/PAIN/B88). 
 
4. Discussion  
We identified knee OA subgroups/phenotypes based on pain trajectories. The number of 
trajectory-groups, their size and pattern of development differed due to study inclusion 
criteria, sample size and follow-up duration of the VIDEO trial and the OAI study. However, 
due to observable similarities, we identified four OA phenotypes from these: low-fluctuating, 
mild-increasing, moderate-treatment-sensitive and severe-treatment-insensitive pain. We 
found that pain and functional limitations in OA measured by WOMAC questionnaire 
showed the same development over time. Importantly, we identified a phenotype with severe 
pain that did not benefit from analgesics and had the same chance for knee replacement as the 
low-fluctuating phenotype. We also identified a subgroup most likely to benefit from knee 
replacement. Finally, using baseline factors, we were able to distinguish painful from 
minimally-painful groups but found little to differentiate moderate from severe pain groups. 
We used two high-quality studies of different design, size and follow-up duration to 
overcome some of their complementary drawbacks. Unlike some previous studies, ours did 
not employ any method to additionally select/match participants or make the two studies 
more similar [6; 26]. Instead, we relied on a method that selected latent classes for dealing 
with heterogeneity [23]. In group-based modelling, we permitted small groups to be detected 
when the model fit supported it. We also managed to replicate the small-sized groups, 
reducing the chance of spurious classes’ detection. Although studies had different intervals of 
the outcome assessment, it provided additional evidence of the consistency and robustness of 
the findings. Both studies involved OA patients at different disease stages. The baseline in 
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each case was related to the study; it is not the disease baseline, as there is still a lack of OA 
onset definition in the field overall [19]. However, our studies had different follow-up 
durations, allowing us to observe time-effects more comprehensively. On the other hand, due 
to different follow-up durations, we did not directly compare trajectory-groups between the 
samples. Although different inclusion and exclusion criteria employed to some extent, 
samples were similar in terms of demographic and lifestyle factors. As expected, trial 
participants were more severe in clinical and radiographic aspects. We used a set of baseline 
characteristics that did not entirely overlap. Although this was a study limitation, it 
represented the diversity of OA covariate measures used. 
There were four phenotypes identified in the trial and replicated in the OAI study. We named 
phenotypes by indicating baseline pain and its pattern or responsiveness to treatments. The 
minimal pain trajectory-group from the OAI study represented people with minimal-to-
neglected knee pain, thus not assumed an OA phenotype. These were sampled in the cohort 
but not the trial. The first trajectory-group selected in the VIDEO trial and the second 
trajectory-group in the OAI study presented the low-fluctuating phenotype. In the short-term, 
it showed pain improvement but fluctuated in the long-term, albeit staying quite low. This 
phenotype included slightly more than a third of both samples and reflected reports from 
previous studies [3; 6; 26; 27]. The second trajectory-group in the trial and the third in the 
cohort represented the second mild-increasing phenotype (also reported before) [6; 26]. This 
phenotype is the only more common one in the trial than in the cohort. The remarkable 
observation was related to the third moderate-treatment-sensitive phenotype: third trajectory-
group in the trial and the fourth and fifth groups in the cohort. In a three-year window, this 
phenotype presented moderate-increasing pain in both studies. However, longer-term, this 
phenotype divided into two subgroups: in one, patients benefited from knee replacement 
(fourth trajectory), while in another, patients continued to experience moderate pain despite 
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significant analgesic effects (fifth trajectory). This phenotype included 15–20% of the 
samples. Similar observations were found in studies using the CAS-K [26] and CHECK [3] 
cohort, but not in the five-trajectory model previously identified in the OAI study [6; 26]. 
However, previous studies did not examine treatment effects on pain trajectories. Finally, the 
fourth phenotype included 3% of both our samples. It was also shown earlier [3; 6; 26] and 
here additionally described by severe-treatment-insensitive pain (fourth group in the trial and 
sixth group in the cohort).  
Further, we found that functional limitations followed identical development to pain, 
indicating that people experienced these two outcomes very similarly or could not distinguish 
between them. Some studies examined functional limitation in knee OA [11; 32], but none of 
these did not look into interplay between pain and functional limitation over time. While the 
first three phenotypes were responsive to currently available analgesics, the fourth was not. 
OA phenotypes were not significantly associated with knee replacement during a three-year 
follow-up, as only a few replacements took place during the period. However, in the longer-
term – as the number of replacements increased – mild-increasing and moderate-treatment-
sensitive phenotypes but not severe-treatment-insensitive had significant odds of having knee 
replacement when compared to the mild-fluctuating one. The severe-treatment-insensitive 
phenotype in the OAI study included the youngest women with the highest BMI and 
depression score, with more comorbidities, using analgesics, but without pain relief. The left 
and right knee trajectories and their dual model showed that most people develop the same 
pain pattern irrespective of laterality, probably due to central pain processing. The 
overlapping group percentage was likely lower due to individuals’ unilateral pathologies. 
The baseline clinical and lifestyle factors in our study were modest in differentiating the 
phenotypes. Overall, the variable with a consistently positive relationship to pain seemed to 
be BMI, indicating metabolic differences between phenotypes. The age effect was transposed 
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between study samples. As previously discussed, the exclusion criteria in the OAI study 
likely led to a healthier population being selected [6]. More generally, age-effect can be a 
random observation unrelated to pain phenotypes, instead indicating time-dependent 
exposure and a molecular process to be detected. Interestingly, 75% of the fourth phenotype 
were women, indicating a sex-specific mechanism of severe-treatment-insensitive pain. 
Finally, the nine-year follow-up is the longest regular/annual follow-up so far in knee OA, 
and it has given us better insights into long-term pain, the slow-progressing character of OA 
and its relation to OA end-stage.  
To conclude, our approach provided robust results regarding pain experience for OA patient 
phenotyping with clinical, research and trial-design relevance. Pain should remain the 
primary outcome under investigation, as functional limitations do not add information. 
Besides pain duration, we should also consider pain intensity. The cut-off for inclusion in 
clinical trials should be pain intensity above 20%, and for the sensitivity analyses above 50% 
of the scale. This range is also the indicator for delivery of currently available treatments. 
Patients experiencing pain above 50% of the scale need novel pharmacological treatments 
and careful consideration of safety issues due to comorbidities. Due to the reproducibility 
between study designs, it creates a template for re-analysing available longitudinal data pools 
with further characterisation. To improve phenotype differentiation beyond this report, we 
suggest employing molecular and genetic tools [9] that should provide inside into 
dysregulated molecular pathways to target. Then pain with additional tools will lead to an 
optimal set of criteria for selecting patients for treatment options and future OA clinical trials. 
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Figure 1 Trajectories – red colour (-1-) indicates the first trajectory-group, green (-2-) the 
second, blue (-3-) the third, black (-4-) the fourth, yellow (-5-) the fifth, and orange (-6-) the 
sixth group; a) pain trajectories in the VIDEO trial; b) functional limitation trajectories in the 
VIDEO trial; c) pain trajectories in the OAI study with a window of three-year follow-up 
comparable to the VIDEO trial duration; people with minimal-to-neglected knee pain – 
trajectory one; low-fluctuating phenotype – trajectory two corresponding to the trajectory one 
in the VIDEO trial; mild-increasing phenotype – trajectory three corresponding to the 
trajectory two in the VIDEO trial; moderate-treatment-sensitive phenotype – trajectories four 
and five corresponding to the trajectory three in the VIDEO trial; high-treatment-insensitive 
phenotype corresponding to the trajectory four in the VIDEO trial; d) functional limitation 
trajectories in the OAI study with a window of three-year follow-up equivalent to the VIDEO 
trial duration. 
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Table 1 Baseline descriptive statistics of the study samples 
 The VIDEO trial  
N=474 
Follow-up 3 years 
The OAI study  
N=4796 
Follow-up 9 years 
 
Variable  
 
N 
 
% 
Mean (SD) /  
Median (IQR) 
 
N 
 
% 
Mean (SD) /  
Median (IQR) 
Treatment 
Active 
 
23
7 
 
50.0 
 N/A 
Vitamin D 
Active 
 
Placebo 
 
Missing 
 
23
2 
 
23
1 
 
11 
 
 
 
 
 
2.3 
 
22.9 (8.8) /  
21.9 (16.3-
28.3) 
23.0 (8.0) / 
22.3 (16.7-
28.8) 
  
N/A 
Age 
 
Missing 
47
4 
 
0 
 64.0 (7.6) / 
63.0 (58.0-
69.0) 
4500 
 
296 
 
 
6.2 
61.3 (9.2) /  
61.0 (53.0-
69.0) 
Sex  
Women 
 
28
9 
 
61.0 
  
2804 
 
58.5 
 
Body mass index 
 
Missing 
47
3 
 
1 
 
 
0.2 
29.4 (5.1) / 
28.7 (25.5-
32.3) 
4792 
 
4 
 
 
0.1 
28.6 (4.8) /  
28.3 (25.1-
31.7) 
Smoking 
Current 
Current-not regular 
Former 
Never smoked 
Missing 
 
25 
 
21
4 
23
0 
5 
 
5.2 
 
45.2 
48.5 
1.1 
  
313 
10 
1909 
2564 
0 
 
6.5 
0.2 
39.8 
53.5 
 
 
Alcohol use 
Yes 
Missing 
 
39
5 
0 
 
83.3 
  
3821 
0 
 
79.7 
 
 
Currently working  
Yes 
Missing 
 
19
8 
1 
 
41.8 
0.2 
  
2943 
0 
 
61.4 
 
 
Physical activity  
Sport/hobby>1/month 
Yes 
Missing  
 
 
22
4 
 
 
47.3 
0.8 
 N/A  
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Depression 
Beck’s Depression 
Inventory  
(score 0-63) 
Centre for 
Epidemiological 
Studies Depression Scale 
(score 0-60) 
Missing 
 
47
3 
 
 
 
 
1 
 
 
 
 
 
 
0.2 
 
2.0 (2.6) / 
1.0 (0.0-3.0) 
 
 
 
4731 
 
 
65 
 
 
 
 
 
 
1.4 
 
 
 
6.6 (7.0) /  
4.0 (2.0-9.0) 
Quality of Life  
WHOQoL-Bref (score 0-
100) 
Physical domain 
 
Psychological domain  
 
Social domain 
 
Environmental domain  
 
Missing 
 
 
46
8 
 
46
8 
 
46
8 
 
46
8 
 
6 
 
 
 
 
 
 
 
 
 
 
1.3 
 
 
64.5 (16.6) / 
64.3 (53.6-
75.0) 
71.2 (14.3) / 
70.8 (62.5-
79.2) 
71.9 (18.8) / 
75.0 (58.3-
83.3) 
77.4 (13.0) / 
78.1 (68.8-
87.5) 
 
N/A 
 
 
Comorbidities 
None 
One 
More than one 
Missing 
N/A 
 
 
  
3631 
724 
441 
0 
 
75.7 
15.1 
9.2 
 
 
Medications 
Use of analgesics, 
NSAIDs and steroids 
Yes 
Missing 
 
 
 
27
3 
17 
 
 
 
57.6 
3.6 
  
 
 
1783 
0 
 
 
 
37.2 
 
 
Supplements 
Use of glucosamine and 
chondroitin  
Yes  
Missing 
 
 
 
13
9 
17 
 
 
 
29.3 
3.6 
  
 
 
1625 
0 
 
 
 
33.9 
 
 
Kellgren-Lawrence 
grade (Index/Worse 
knee)a 
0 
1 
2 
3 
4 
 
 
6 
12
1 
17
8 
13
 
 
1.3 
25.5 
37.6 
28.7 
6.1 
0.8 
  
 
1260 
697 
1365 
892 
293 
289 
 
 
26.3 
14.5 
28.5 
18.6 
6.1 
6.0 
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Missing 6 
29 
4 
Knee replacement 
At baseline 
Yes 
Left 
Right 
No 
Missing 
 
 
 
 
 
47
4 
0 
 
 
 
 
 
100.0 
  
 
63 
25 
38 
4733 
0 
 
 
1.3 
0.5 
0.8 
98.7 
 
 
Knee replacement  
During follow-up 
Left 
Right 
Bilateral replacement 
Index 
Contralateral 
 
 
 
 
2 
13 
30 
 
 
 
 
0.4 
2.7 
6.3 
  
 
271 
277 
119 
 
 
5.7 
5.8 
2.5 
 
Individuals with knee 
replacement by the end of 
the studyb 
Yes 
No 
 
 
41 
43
3 
 
 
8.6 
91.4 
  
 
492 
4357 
 
 
9.2 
90.8 
 
Mortality  
During follow-up 
Yes 
 
 
5 
 
 
1.1 
  
 
305 
 
 
6.4 
 
SD – standard deviation; IQR – interquartile range; N/A – not applicable or not assessed; 
WHOQoL-Bref – The World Health Organisation Quality of Life Instrument; NSAID – 
non-steroid anti-inflammatory drug. 
a
 – The index knee refers to the VIDEO trial, and the Worse knee to the OAI study. 
b 
– The summary of the previous two variables, knee replacement at baseline and during 
follow-up, showing information per person instead of per knee. 
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Table 2 Pain trajectory modelling 
The main model a Dual 
trajectory 
model b 
Model with time-varying 
covariate c 
TG Intercept Curve 
order 
Group 
% 
Post. 
Prob. 
Group 
% 
Post. 
Prob. 
Group 
% 
Post. 
Prob. 
Covariate  
Estimate (95% 
CI) 
The VIDEO trial 
1 17.6 1 36.5 0.90 31.6 0.93 35.0 0.90 2.6 (0.3-4.9) 
2 30.5 1 39.7 0.85 36.1 0.88 40.7 0.86 3.1 (0.9-5.3) 
3 48.0 1 20.5 0.91 20.0 0.88 21.3 0.89 -1.1 (-4.2-2.0) 
4 71.5 1 3.4 0.89 12.2 0.92 3.0 0.93 -3.6 (-10.3-
3.1) 
The OAI study 
1 -7.4d 3 22.8 0.90 22.9 0.94 22.4 0.88 8.2 (6.9-9.5) 
2 8.6 4 37.2 0.87 31.6 0.89 39.8 0.85 8.2 (7.6-8.9) 
3 18.6 2 22.5 0.83 20.6 0.86 21.4 0.80 7.2 (6.3-8.1) 
4 38.4 3 3.4 0.80 6.8 0.86 10.4 0.83 7.1 (5.8-8.3) 
5 39.7 2 11.2 0.84 13.4 0.88 3.8 0.87 16.0 (13.6-
18.5) 
6 59.8 2 3.0 0.89 4.6 0.92 2.1 0.79 0.1 (-2.9-3.0) 
TG – Trajectory-group; Post. prob. – posterior probability; CI – confidence interval. 
a The model was created using WOMAC pain repeated measures. 
b The model was created using WOMAC pain repeated measures given the WOMAC 
Functional limitation trajectories. 
c
 The model was created using WOMAC pain repeated measures adjusted for medication use 
as a time-varying covariate during the follow-up. The model assumption was ‘no use’ at all-
time points; thus, the covariate estimates are positive and indicate that the use of medication 
was reducing the pain. In the OAI study only, medication use is missing at follow-up year 
three; thus, pain trajectories were redone without year three, fully reproduced as with year 
three data, and in that model, the time-varying medication use was included. This model did 
not fully converge. The analysis was redone numerous times, and the estimates were always 
the same as reported here.  
d The estimate is negative but the actual minimum of the scale is zero. 
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Table 3 Pain trajectories as predictors of knee replacement 
The VIDEO trial The OAI study 
 
Pain 
Trajectory 
ORa  
(95% CI) 
Index knee 
 
Pain 
Trajectory 
HRb 
 (95% CI) 
Left knee 
HRb  
(95% CI) 
Right knee 
HRb  
(95% CI) 
Generalised 
1 Reference 2 Reference 
2 7.0 (0.8-59.0) 3 2.5 (1.8-3.7) 2.4 (1.7-3.5) 1.3 (1.1-1.7) 
3 4.8 (0.4-55.9) 4 13.8 (9.4-20.2) 11.9 (8.1-17.6) 
4.6 (3.4-6.4) 
5 3.8 (2.4-5.8) 3.5 (2.3-5.3) 1.8 (1.3-2.4) 
4 16.6 (0.9-
308.6) 
6 4.3 (2.0-8.9) 1.8 (0.7-4.6) 1.3 (0.7-2.3) 
OR – odds ratio; CI – confidence interval; HR – hazard ratio. Number of observations used 
in the VIDEO trial models was 425, and in the OAI study without trajectory group 1, it was 
2827 for the left knee, 3049 for the right knee and 3348 for the generalised model, 
depending on the missing values of Kellgren-Lawrence grade at baseline. 
All models were constructed using forward selection procedure. In the VIDEO trial, 
variables included in the selection were pain trajectory-group, treatment, vitamin D, 
interaction treatment and vitamin D, age, sex, body mass index, smoking, alcohol drinking, 
currently working, physical activity, Beck’s depression scale, physical, psychological, 
social and environment domains of the quality of life, Kellgren-Lawrence grade of the 
index knee at baseline, use of medications and use of supplements at baseline. In the OAI 
study, variables included in the model were pain trajectory-group, age, sex, body mass 
index, smoking, alcohol drinking, currently working, Centre for Epidemiological Studies 
Depression score, comorbidities, Kellgren-Lawrence of the examined knee at baseline, 
knee replacement at baseline, use of medications and use of supplements at baseline. The 
estimates presented were from the final models. 
a
 The model was constructed using binary logistic regression model and included pain 
trajectory-group (forced entry for the report), vitamin D main effect and currently working. 
b
 The models was constructed using Cox proportional hazards model, and all three included 
pain trajectory-group, age, Centre for Epidemiological Studies Depression score, Kellgren-
Lawrence of the examined knee at baseline, use of medications and use of supplements at 
baseline; in addition to these, left knee model included also sex and comorbidities, right 
knee model smoking, and the generalised model knee replacement at baseline. 
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 The VIDEO trial 
N=474 
The OAI cohort 
N=4796 
Trajectory-group 
Phenotype 
 
 
 
 
Variables 
1  
low-
fluctuatin
g 
 
N=173  
36.4% 
2  
mild-
increasin
g 
 
N=188 
39.7% 
3 
moderate
-
treatment
-sensitive 
N=97  
20.5% 
4  
severe-
treatment-
insensitiv
e 
N=16 
3.4% 
1 
none 
 
 
N=109
3 
22.8% 
2 
low-
fluctuatin
g 
 
N=1782 
37.2% 
3 
mild-
increasin
g 
 
N=1078 
22.5% 
4 
moderate
-
treatment
-sensitive 
N=163  
3.4% 
5 
moderate
-
treatment
-sensitive 
N=535 
11.2% 
6 
severe-
treatment-
insensitiv
e 
N=145  
3.0% 
Age (median, IQR) 
 
Missing (%) 
62.0 
(58.0-
68.0) 
0.0 
64.0 
(58.0-
71.0) 
0.0 
64.0 
(59.0-
69.0) 
0.0 
66.0 
(61.3-
67.8) 
0.0 
62.0 
(53.5-
70.0) 
5.1 
61.0 
(53.5-
68.0) 
5.0 
61.0 
(54.0-
69.0) 
5.7 
62.0 
(55.0-
69.0) 
2.5 
60.0 
(53.0-
68.8) 
11.8 
56.0 
(51.8-
63.0) 
15.9 
Sex (%)  
Women 
 
59.5 
 
63.3 
 
56.7 
 
75.0 
 
53.1 
 
58.0 
 
58.0 
 
68.1 
 
64.9 
 
74.5 
Body mass index 
(median, IQR) 
Missing (%) 
27.7 
(24.8-
30.2) 
0.6 
28.8 
(25.4-
32.3) 
0.0 
30.8 
(27.8-
35.1) 
0.0 
32.8 
(28.6-
38.8) 
0.0 
26.4 
(23.6-
29.8) 
0.0 
27.7 
(24.7-
31.1) 
0.1 
29.1 
(25.9-
32.4) 
0.2 
29.2 
(26.5-
32.5) 
0.0 
30.4 
(27.4-
34.3) 
0.2 
32.7 
(28.0-
37.4) 
0.0 
Smoking (%) 
Current 
Current-not regular 
Former 
Never smoked 
Missing 
 
3.5 
 
45.1 
49.7 
1.7 
 
5.3 
 
45.2 
48.9 
0.5 
 
6.2 
 
48.5 
44.3 
1.0 
 
18.8 
 
25.0 
56.3 
0.0 
 
3.6 
0.2 
36.0 
60.2 
0.0 
 
4.9 
0.3 
39.6 
55.2 
0.0 
 
5.7 
0.3 
44.3 
49.7 
0.0 
 
15.3 
0.0 
41.8 
42.9 
0.0 
 
13.3 
0.0 
40.9 
45.8 
0.0 
 
20.7 
0.0 
31.0 
48.3 
0.0 
Alcohol use (%) 
Yes 
Missing 
 
83.8 
0.0 
 
83.5 
0.0 
 
82.5 
0.0 
 
81.3 
0.0 
 
84.2 
0.0 
 
81.6 
0.0 
 
80.5 
0.0 
 
77.3 
0.0 
 
68.8 
0.0 
 
57.9 
0.0 
Currently working 
(%) 
Yes 
 
52.6 
0.0 
 
39.4 
0.0 
 
28.9 
0.0 
 
33.3 
6.3 
 
63.7 
0.0 
 
64.6 
0.0 
 
58.5 
0.0 
 
54.0 
0.0 
 
56.4 
0.0 
 
51.0 
0.0 
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Missing  
Physical activity 
(%) 
Sport/hobby>1/mont
h  
Yes 
Missing 
 
 
53.8 
0.6 
 
 
48.9 
1.1 
 
 
35.1 
0.0 
 
 
40.0 
6.3 
N/A 
Depression 
Beck’s Depression 
Inventory (median, 
IQR) 
Centre for 
Epidemiological 
Studies Depression 
Scale (median, IQR) 
Missing (%) 
 
1.0 
(0.0-2.0) 
 
 
 
 
0.0 
 
1.0 
(0.0-4.0) 
 
 
 
 
0.5 
 
1.0 
(1.0-4.0) 
 
 
 
 
0.0 
 
2.0 
(0.3-4.5) 
 
 
 
 
0.0 
 
 
 
3.0 
(1.0-
6.0) 
 
 
0.6 
 
 
 
4.0 
(2.0-8.0) 
 
 
1.5 
 
 
 
5.0 
(2.0-11.0) 
 
 
0.9 
 
 
 
7.0 
(3.0-12.8) 
 
 
1.8 
 
 
 
7.0 
(3.0-14.0) 
 
 
2.8 
 
 
 
13.0 
(5.0-21.0) 
 
 
2.8 
Quality of Life 
WHOQoL-Bref  
(median, IQR) 
Physical domain 
 
Psychological 
domain  
 
Social domain 
 
Environmental 
domain  
 
Missing (%) 
 
 
 
75.0 
(64.3-
82.1) 
75.0 
(66.7-
80.0) 
75.0 
(66.7-
83.3) 
81.3 
(71.9-
90.6) 
1.2 
 
 
 
64.3 
(53.6-
75.0) 
70.8 
(62.5-
79.2) 
75.0 
(58.3-
83.3) 
78.1 
(68.8-
84.4) 
1.1 
 
 
 
57.1 
(42.9-
64.3) 
70.8 
(60.0-
79.2) 
66.7 
(58.3-
83.3) 
75.0 
(65.6-
84.4) 
2.1 
 
 
 
55.4 
(32.1-
59.8) 
66.7 
(58.3-
74.0) 
66.7 
(52.1-
75.0) 
68.8 
(62.5-
83.6) 
0.0 
N/A 
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Comorbidities (%) 
None 
One 
More than one 
Missing 
N/A  
82.2 
10.9 
6.9 
0.0 
 
79.6 
13.5 
6.9 
0.0 
 
74.3 
16.0 
9.7 
0.0 
 
70.5 
17.2 
12.3 
0.0 
 
59.6 
23.0 
17.4 
0.0 
 
53.8 
28.3 
17.9 
0.0 
Medications (%) 
Use of analgesics, 
NSAIDs and steroids  
Yes 
Missing 
 
 
 
47.4 
6.9 
 
 
 
59.0 
1.6 
 
 
 
69.1 
1.0 
 
 
 
86.7 
6.3 
 
 
 
18.8 
0.0 
 
 
 
30.0 
0.0 
 
 
 
48.1 
0.0 
 
 
 
63.8 
0.0 
 
 
 
58.9 
0.0 
 
 
 
72.4 
0.0 
Supplements (%) 
Use of glucosamine 
and chondroitin  
Yes  
Missing (%) 
 
 
 
36.4 
6.9 
 
 
 
29.3 
1.6 
 
 
 
20.6 
1.0 
 
 
 
6.7 
6.3 
 
 
 
26.6 
0.0 
 
 
 
36.1 
0.0 
 
 
 
39.8 
0.0 
 
 
 
36.2 
0.0 
 
 
 
33.5 
0.0 
 
 
 
15.9 
0.0 
Kellgren-Lawrence 
grade (%) 
(Index/Worse knee)a 
0 
1 
2 
3 
4 
Missing (%) 
 
 
 
2.3 
27.7 
39.9 
25.4 
4.6 
0.0 
 
 
 
0.0 
24.2 
38.7 
29.6 
7.5 
1.1 
 
 
 
2.1 
22.7 
34.0 
35.1 
5.2 
1.0 
 
 
 
0.0 
37.5 
25.0 
18.8 
12.5 
6.3 
 
 
 
41.1 
19.4 
23.0 
9.1 
1.3 
6.2 
 
 
 
28.6 
16.4 
30.9 
15.2 
4.2 
4.7 
 
 
 
18.7 
11.3 
28.8 
26.3 
9.6 
5.3 
 
 
 
11.0 
12.3 
25.8 
27.0 
22.1 
1.8 
 
 
 
12.9 
7.1 
31.0 
27.9 
10.3 
10.8 
 
 
 
8.3 
8.3 
31.0 
32.4 
6.9 
13.1 
Knee replacement 
(%) 
At baseline 
Left 
Right 
N/A  
 
0.5 
0.5 
 
 
0.4 
0.7 
 
 
0.4 
1.0 
 
 
1.2 
0.6 
 
 
1.1 
1.3 
 
 
0.0 
0.7 
Knee replacement 
(%) 
During follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.6 
 
 
3.3 
 
 
7.5 
 
 
31.9 
 
 
11.4 
 
 
7.6 
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Left 
Right 
Bilateral 
Index 
Contralateral  
Bilateral 
 
 
1.2 
5.2 
0.6 
 
 
3.7 
4.3 
0.0 
 
 
2.1 
10.3 
1.0 
 
 
12.5 
18.8 
0.0 
0.7 
0.4 
3.8 
1.4 
8.3 
3.1 
30.7 
19.6 
10.7 
4.3 
4.1 
1.4 
Mortality (%) 
Yes 
 
0.6 
 
1.1 
 
1.0 
 
6.3 
 
6.2 
 
5.9 
 
6.3 
 
3.7 
 
9.7 
 
4.1 
IQR – interquartile range; N/A – not applicable or not assessed; WHOQoL-Bref – The World Health Organisation Quality of Life Instrument; 
NSAID – non-steroid anti-inflammatory drug; N/A – not applicable due to exclusion criteria. 
a
 – Index knee refers to the VIDEO trial, and Worse knee to the OAI study. 
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